ALNYLAM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALNYLAM, and when can generic versions of ALNYLAM drugs launch?
ALNYLAM has four approved drugs.
There are forty-five US patents protecting ALNYLAM drugs.
There are seven hundred and eighty-nine patent family members on ALNYLAM drugs in fifty-four countries and eighty supplementary protection certificates in seventeen countries.
Drugs and US Patents for ALNYLAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 11,446,380 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 11,079,379 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 9,708,615 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 8,106,022 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 10,208,307 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 10,273,477 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 10,478,500 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALNYLAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 9,708,615 | ⤷ Sign Up |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,778,902 | ⤷ Sign Up |
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 10,273,477 | ⤷ Sign Up |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,362,231 | ⤷ Sign Up |
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 8,546,143 | ⤷ Sign Up |
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 11,530,408 | ⤷ Sign Up |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 9,567,582 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALNYLAM Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 2021038 | ⤷ Sign Up |
Taiwan | I727963 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2004043979 | ⤷ Sign Up |
Japan | 2020526553 | ⤷ Sign Up |
China | 116064515 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2010048228 | ⤷ Sign Up |
Eurasian Patent Organization | 036772 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALNYLAM Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3204015 | C03204015/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: LUMASIRANUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68239 01.12.2021 |
2937418 | 1990004-2 | Sweden | ⤷ Sign Up | PRODUCT NAME: PATISIRAN; REG. NO/DATE: EU/1/18/1320 20180829 |
2937418 | 682 | Finland | ⤷ Sign Up | |
3052628 | SPC/GB20/042 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/20/1428 (NI) 20200304; UK PLGB 50597/0004 20200304 |
3581654 | CA 2021 00038 | Denmark | ⤷ Sign Up | PRODUCT NAME: LUMASIRAN; REG. NO/DATE: EU/1/20/1496 20201123 |
3052628 | CR 2020 00042 | Denmark | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1428 20200304 |
3052628 | 2090037-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/20/1428 20200304 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.